Lyra Therapeutics (OTCMKTS:LYRA – Get Free Report) is projected to issue its resultson Tuesday, November 17th. Analysts expect Lyra Therapeutics to post earnings of ($1.63) per share and revenue of $0.10 million for the quarter.
Lyra Therapeutics Price Performance
OTCMKTS:LYRA opened at $0.19 on Tuesday. Lyra Therapeutics has a 52-week low of $0.00 and a 52-week high of $5.65. The stock has a fifty day simple moving average of $0.18 and a 200-day simple moving average of $0.63.
Lyra Therapeutics Company Profile
Lyra Therapeutics is a biotechnology company focused on developing long-acting, locally administered treatments for diseases of the ear, nose and throat. The company’s programs are designed to deliver medication directly to the nasal passages, with the goal of improving treatment duration, reducing reliance on daily therapies and addressing limitations associated with conventional nasal sprays.
Lyra’s technology is based on its proprietary, bioresorbable nasal delivery platform, which is intended to provide controlled drug release over an extended period.
Read More
- Five stocks we like better than Lyra Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Lyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
